June 29, 2017 6:34 AM ET


Company Overview of Rafael Pharmaceuticals, Inc.

Company Overview

Rafael Pharmaceuticals, Inc. operates as a clinical-stage metabolic oncology therapeutics company that manufactures anti-cancer agents with minimal toxic effects on normal cells and tissues to treat cancers. It researches and develops in the areas of cancer metabolism; an altered energy metabolism directed drug platform; and CPI-613 that targets the mitochondrial tricarboxylic acid cycle. Rafael Pharmaceuticals, Inc. was formerly known as Cornerstone Pharmaceuticals, Inc. and changed its name to Rafael Pharmaceuticals, Inc. in June 2017. The company was founded in 2000 and is based in Cranbury, New Jersey. Rafael Pharmaceuticals, Inc. operates as a subsidiary of Chiesi USA, Inc.

1 Duncan Drive

Cranbury, NJ 08512

United States

Founded in 2000

14 Employees





Key Executives for Rafael Pharmaceuticals, Inc.

President and General Counsel
Age: 44
Chief Financial Officer, Principal Accounting Officer and Vice President
Age: 71
Chief Operating Officer, Treasurer and Director
Age: 54
Chief Medical Officer
Chief Business Officer
Compensation as of Fiscal Year 2016.

Rafael Pharmaceuticals, Inc. Key Developments

Cornerstone Pharmaceuticals, Inc. has Changed its Name to Rafael Pharmaceuticals, Inc

On June 05, 2017, Cornerstone Pharmaceuticals, Inc. changed its name to Rafael Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc. Presents at Seventh Annual BioPartnering Conference, May-23-2017 01:45 PM

Cornerstone Pharmaceuticals, Inc. Presents at Seventh Annual BioPartnering Conference, May-23-2017 01:45 PM. Venue: Busch Campus Center, Rutgers University, 604 Bartholomew Road, Piscataway, NJ 08854, United States. Speakers: Sanjeev Luther, Chief Business Officer.

Cornerstone Pharmaceuticals, Inc. Announces the Publication of Data from A Phase I Trial Evaluating Its Lead Compound, CPI-613

Cornerstone Pharmaceuticals, Inc. announced the publication of data from a Phase I trial evaluating its lead compound, CPI-613, in combination with a modified FOLFIRINOX regimen in patients with metastatic pancreatic cancer. The data, published in the current issue of the Lancet Oncology, provides preliminary evidence of CPI-613 based combination therapy exhibiting efficacy improvement over currently approved treatments while also showing that the CPI-613 combination was safe and well tolerated. CPI-613 is Cornerstone Pharmaceuticals’ lead Altered Energy Metabolism Directed (AEMD) drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways in cancer cells by targeting mitochondrial metabolism. It selectively targets the mitochondrial tricarboxylic acid (TCA) cycle in cancer cells, an indispensable process essential to cell multiplication and survival. By providing evidence of safety, tolerability, and preliminary efficacy, the Phase I data provides direction for further investigation of CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer, including a forthcoming Phase II/III trial of the combination. Pancreatic cancer is the fourth-leading cause of cancer-related death in the United States, with a 5-year survival rate of just 7%. More than half (53%) of patients are diagnosed at the advanced stages of the disease, when treatment is considered to be only palliative. The most commonly used treatments are FOLFIRINOX, a four-drug combination consisting of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin; and gemcitabine plus nab-paclitaxel. These treatments provide a median overall survival of 11.1 months and 8.5 months, respectively. However, long-term survival has been reported to be rare with these agents, and their toxicity usually restricts their use to patients with good performance status.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Rafael Pharmaceuticals, Inc., please visit www.cornerstonepharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.